Laurent J Servais

List of Publications by Year
in descending order

134	7,471	57758	60623
papers	citations	44 h-index	81 g-index

139	139	139	6950
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Developmental Medicine and Child Neurology, 2023, 65, 67-77.	2.1	20
2	Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placeboâ€controlled, doseâ€finding trial followed by 24â€‰months of treatment. European Journal of Neurology, 2023, 30, 1945-1956.	3.3	23
3	Genotypeâ€related respiratory progression in Duchenne muscular dystrophyâ€”A multicenter international study. Muscle and Nerve, 2022, 65, 67-74.	2.2	8
4	Homeâ€based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type <scp>R2</scp> and facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 65, 237-242.	2.2	8
5	Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Therapeutics, 2022, 32, 29-39.	3.6	58
6	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	10.2	89
7	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscular Disorders, 2022, 32, 271-283.	0.6	13
8	Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert Opinion on Investigational Drugs, 2022, 31, 451-461.	4.1	17
9	Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials. Journal of Neuromuscular Diseases, 2022, 9, 335-346.	2.6	25
10	Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatric Pulmonology, 2022, 57, 1505-1512.	2.0	5
11	Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. Expert Opinion on Biological Therapy, 2022, 22, 1075-1090.	3.1	13
12	Response of plasma <scp>microRNAs</scp> to nusinersen treatment in patients with <scp>SMA</scp>. Annals of Clinical and Translational Neurology, 2022, 9, 1011-1026.	3.7	6
13	INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular Myopathy. Journal of Neuromuscular Diseases, 2022, 9, 503-516.	2.6	5
14	Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature Medicine, 2022, 28, 1381-1389.	30.7	99
15	Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nature Medicine, 2022, 28, 1390-1397.	30.7	93
16	Emerging therapies for Duchenne muscular dystrophy. Lancet Neurology, The, 2022, 21, 814-829.	10.2	35
17	Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy. Annals of Neurology, 2021, 89, 280-292.	5.3	32
18	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. European Radiology, 2021, 31, 4264-4276.	4.5	19

#	Article	IF	Citations
19	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	1.6	1
20	Diagnosing X-linked Myotubular Myopathy â€“ A German 20-year Follow Up Experience. Journal of Neuromuscular Diseases, 2021, 8, 79-90.	2.6	12
21	Remote Digital Monitoring for Medical Product Development. Clinical and Translational Science, 2021, 14, 94-101.	3.1	14
22	Use of the Childrenâ€™s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance. Journal of Neuromuscular Diseases, 2021, 8, 63-77.	2.6	9
23	Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy. Orphanet Journal of Rare Diseases, 2021, 16, 3.	2.7	21
24	The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy. Acta Neuropathologica Communications, 2021, 9, 7.	5.2	24
25	Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet Journal of Rare Diseases, 2021, 16, 47.	2.7	54
26	Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy. Scientific Reports, 2021, 11, 3011.	3.3	14
27	Risdiplam in Type 1 Spinal Muscular Atrophy. New England Journal of Medicine, 2021, 384, 915-923.	27.0	229
28	Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opinion on Investigational Drugs, 2021, 30, 519-527.	4.1	14
29	Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 677-693.	7.3	25
30	Prognostic Factors and Treatmentâ€Effect Modifiers in Spinal Muscular Atrophy. Clinical Pharmacology and Therapeutics, 2021, 110, 1435-1454.	4.7	7
31	Therapies in preclinical and clinical development for Angelman syndrome. Expert Opinion on Investigational Drugs, 2021, 30, 709-720.	4.1	22
32	Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscular Disorders, 2021, 31, 574-582.	0.6	94
33	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	2.5	6
34	Newborn screening of neuromuscular diseases. Neuromuscular Disorders, 2021, 31, 1070-1080.	0.6	9
35	Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet Journal of Rare Diseases, 2021, 16, 318.	2.7	9
36	E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. Journal of Neuromuscular Diseases, 2021, 8, 743-754.	2.6	2

#	Article	IF	Citations
37	Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases, 2021, 8, 543-551.	2.6	9
38	Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. New England Journal of Medicine, 2021, 385, 427-435.	27.0	137
39	First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. Digital Biomarkers, 2021, 5, 183-190.	4.4	32
40	Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1938-1950.	3.7	9
41	Crowdfunding for neuromuscular disease treatment: the ethical implications. Lancet Neurology, The, 2021, 20, 788-789.	10.2	6
42	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, The, 2021, 20, 832-841.	10.2	112
43	Natural history of Type 2 and 3 spinal muscular atrophy: 2â€year NatHisâ€SMA study. Annals of Clinical and Translational Neurology, 2021, 8, 359-373.	3.7	58
44	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Scientific Reports, 2021, 11, 19922.	3.3	32
45	Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. Frontiers in Pharmacology, 2021, 12, 735912.	3.5	13
46	Video games to measure outcome for children with neuromuscular disorders. Developmental Medicine and Child Neurology, 2020, 62, 266-266.	2.1	1
47	Oligo-astrocytoma in LZTR1-related Noonan syndrome. European Journal of Medical Genetics, 2020, 63, 103617.	1.3	17
48	Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy. Journal of Neurology, 2020, 267, 228-238.	3.6	14
49	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10â€“12, 2019, Hoofdorp, The Netherlands. Neuromuscular Disorders, 2020, 30, 93-103.	0.6	55
50	Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 5-16.	0.6	33
51	Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Developmental Medicine and Child Neurology, 2020, 62, 310-314.	2.1	36
52	ASCâ€1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of Myopathy. Annals of Neurology, 2020, 87, 217-232.	5.3	12
53	250th ENMC International Workshop: Clinical trial readiness in nemaline myopathy 6â€“8 September 2019, Hoofdorp, the Netherlands. Neuromuscular Disorders, 2020, 30, 866-875.	0.6	6
54	Relationship between markers of disease activity and progression in skeletal muscle of GNE myopathy patients using quantitative nuclear magnetic resonance imaging and 31P nuclear magnetic resonance spectroscopy. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1450-1464.	2.0	12

#	Article	IF	Citations
55	Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy. Epigenomics, 2020, 12, 1899-1915.	2.1	4
56	Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology, 2020, 94, e2270-e2282.	1.1	207
57	RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases, 2020, 7, 145-152.	2.6	17
58	Correspondence on: â€œDiscrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?â€•by Kay et al. Genetics in Medicine, 2020, 22, 1913-1914.	2.4	2
59	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	1.6	74
60	Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1178-1189.	4.1	12
61	New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opinion on Pharmacotherapy, 2020, 21, 307-315.	1.8	91
62	Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy. Journal of Neurology, 2020, 267, 2022-2028.	3.6	13
63	Spinal muscular atrophy care in the COVIDâ€19 pandemic era. Muscle and Nerve, 2020, 62, 46-49.	2.2	31
64	Randomisation versus prioritisation in a managed access programme: Lessons from spinal muscular atrophy. Neuromuscular Disorders, 2020, 30, 267-269.	0.6	5
65	FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). , 2020, , .		6
66	Reader response: Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology, 2020, 95, 144-145.	1.1	7
67	Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1153-1161.	2.0	135
68	Home-Based Monitor for Gait and Activity Analysis. Journal of Visualized Experiments, 2019, , .	0.3	15
69	â€œThe Times They Are a-Changinâ€™.â€•In reply to El-Zaidy et al.: AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Diseases, 2019, 6, 319-320.	2.6	2
70	Odalisque's Position as aGeste Antagonistein a Variant Phenotype of Ataxiaâ€Telangiectasia. Movement Disorders Clinical Practice, 2019, 6, 413-414.	1.5	0
71	X-linked myotubular myopathy. Neurology, 2019, 92, e1852-e1867.	1.1	66
72	Newborn screening for SMA in Southern Belgium. Neuromuscular Disorders, 2019, 29, 343-349.	0.6	65

#	Article	IF	Citations
73	Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Developmental Medicine and Child Neurology, 2019, 61, 19-24.	2.1	115
74	Hearing impairment in patients with myotonic dystrophy type 2. Neurology, 2018, 90, e615-e622.	1.1	11
75	RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect. Molecular Therapy - Nucleic Acids, 2018, 10, 277-291.	5.1	8
76	Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients. Epigenomics, 2018, 10, 875-889.	2.1	23
77	Nusinersen in patients older than 7 months with spinal muscular atrophy type 1. Neurology, 2018, 91, e1312-e1318.	1.1	91
78	STAC3variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. Human Mutation, 2018, 39, 1980-1994.	2.5	42
79	High urinary ferritin reflects myoglobin iron evacuation in DMD patients. Neuromuscular Disorders, 2018, 28, 564-571.	0.6	13
80	Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS ONE, 2018, 13, e0201004.	2.5	107
81	Improved Muscular Weakness During Asthma Exacerbation. JAMA Neurology, 2017, 74, 353.	9.0	2
82	Methylome and transcriptome profiling in Myasthenia Gravis monozygotic twins. Journal of Autoimmunity, 2017, 82, 62-73.	6.5	23
83	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1723-1732.	27.0	1,533
84	DMD and West syndrome. Neuromuscular Disorders, 2017, 27, 911-913.	0.6	5
85	Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nature Communications, 2017, 8, 16105.	12.8	175
86	Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nature Communications, 2017, 8, 1859.	12.8	102
87	Downregulation of the Glial GLT1 Glutamate Transporter and Purkinje Cell Dysfunction in a Mouse Model of Myotonic Dystrophy. Cell Reports, 2017, 19, 2718-2729.	6.4	33
88	A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment. PLoS ONE, 2016, 11, e0156696.	2.5	38
89	Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1. Neuromuscular Disorders, 2016, 26, 428-435.	0.6	22
90	Abnormal Glycosylation Profile and High Alpha-Fetoprotein in a Patient with Twinkle Variants. JIMD Reports, 2016, 29, 109-113.	1.5	5

#	Article	IF	Citations
91	Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea. American Journal of Human Genetics, 2016, 99, 753-761.	6.2	68
92	Mild clinical presentation in KLHL40-related nemaline myopathy (NEM 8). Neuromuscular Disorders, 2016, 26, 712-716.	0.6	16
93	Multidisciplinary care allowing uneventful vaginal delivery in a woman with Pompe disease. Neuromuscular Disorders, 2016, 26, 610-613.	0.6	5
94	EGR2 mutation enhances phenotype spectrum of Dejerineâ€“Sottas syndrome. Journal of Neurology, 2016, 263, 1456-1458.	3.6	5
95	Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy Dystrophinopathy. Human Gene Therapy, 2016, 27, 712-726.	2.7	12
96	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. American Journal of Pathology, 2016, 186, 691-700.	3.8	78
97	Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology, 2016, 86, 1022-1030.	1.1	63
98	Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 550-553.	1.9	73
99	Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy. NMR in Biomedicine, 2015, 28, 1150-1162.	2.8	62
100	Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. Journal of Neuromuscular Diseases, 2015, 2, 269-279.	2.6	21
101	Upper Limb Evaluation and One-Year Follow Up of Non-Ambulant Patients with Spinal Muscular Atrophy: An Observational Multicenter Trial. PLoS ONE, 2015, 10, e0121799.	2.5	49
102	Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 444-446.	0.6	8
103	Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Human Molecular Genetics, 2015, 24, 4916-4932.	2.9	49
104	Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial. PLoS ONE, 2015, 10, e0113999.	2.5	58
105	Severe dystonia, cerebellar atrophy, and cardiomyopathy likely caused by a missense mutation in TOR1AIP1. Orphanet Journal of Rare Diseases, 2014, 9, 174.	2.7	43
106	Serum Profiling Identifies Novel Muscle miRNA and Cardiomyopathy-Related miRNA Biomarkers in Golden Retriever Muscular Dystrophy Dogs and Duchenne Muscular Dystrophy Patients. American Journal of Pathology, 2014, 184, 2885-2898.	3.8	85
107	Muscular Dystrophy. New England Journal of Medicine, 2014, 371, e35.	27.0	3
108	Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial. Neuromuscular Disorders, 2014, 24, 16-24.	0.6	62

#	Article	IF	Citations
109	Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 563-573.	0.6	85
110	Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation. Neuromuscular Disorders, 2014, 24, 993-998.	0.6	6
111	Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients. Molecular Therapy, 2014, 22, 1923-1935.	8.2	108
112	Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurology, The, 2014, 13, 987-996.	10.2	279
113	Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials. Neuromuscular Disorders, 2014, 24, 604-610.	0.6	41
114	Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. Medicine (United States), 2014, 93, 150-157.	1.0	235
115	Development of the <scp>P</scp>erformance of the <scp>U</scp>pper <scp>L</scp>imb module for <scp>D</scp>uchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2013, 55, 1038-1045.	2.1	173
116	Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies. PLoS ONE, 2013, 8, e55281.	2.5	97
117	Aminopyridines Correct Early Dysfunction and Delay Neurodegeneration in a Mouse Model of Spinocerebellar Ataxia Type 1. Journal of Neuroscience, 2011, 31, 11795-11807.	3.6	137
118	High frequency of COH1 intragenic deletions and duplications detected by MLPA in patients with Cohen syndrome. European Journal of Human Genetics, 2010, 18, 1133-1140.	2.8	31
119	BK Channels Control Cerebellar Purkinje and Golgi Cell Rhythmicity In Vivo. PLoS ONE, 2009, 4, e7991.	2.5	39
120	Chiari type I malformation causing central apnoeas in a 4-month-old boy. European Journal of Paediatric Neurology, 2009, 13, 463-465.	1.6	21
121	Immediate Relief of Mycoplasma pneumoniae Encephalitis Symptoms After Intravenous Immunoglobulin. Pediatric Neurology, 2009, 41, 375-377.	2.1	18
122	Effects of maternal alcohol consumption during breastfeeding on motor and cerebellar Purkinje cells behavior in mice. Neuroscience Letters, 2009, 455, 4-7.	2.1	16
123	23 Seksualiteit en verstandelijke beperking. , 2009, , 535-551.		0
124	Purkinje cell dysfunction and alteration of long-term synaptic plasticity in fetal alcohol syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9858-9863.	7.1	97
125	Sexual health care in persons with intellectual disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 2006, 12, 48-56.	3.6	136
126	Targeted calretinin expression in granule cells of calretininnull mice restores normal cerebellar functions. FASEB Journal, 2006, 20, 380-382.	0.5	51

#	Article	IF	Citations
127	Age dependence of strain determinant on mice motor coordination. Brain Research, 2005, 1039, 37-42.	2.2	23
128	Effect of chronic ethanol ingestion on Purkinje and Golgi cell firing in vivo and on motor coordination in mice. Brain Research, 2005, 1055, 171-179.	2.2	27
129	Fast oscillation in the cerebellar cortex of calcium binding protein-deficient mice: a new sensorimotor arrest rhythm. Progress in Brain Research, 2005, 148, 165-180.	1.4	32
130	Inactivation of Calcium-Binding Protein Genes Induces 160 Hz Oscillations in the Cerebellar Cortex of Alert Mice. Journal of Neuroscience, 2004, 24, 434-441.	3.6	106
131	From Electrophysiology to Chromatin: A Bottom-Up Approach to Angelman Syndrome. Annals of the New York Academy of Sciences, 2004, 1030, 599-611.	3.8	24
132	Effect of simple spike firing mode on complex spike firing rate and waveform in cerebellar Purkinje cells in non-anesthetized mice. Neuroscience Letters, 2004, 367, 171-176.	2.1	22
133	Anterior spinal artery syndrome after aortic surgery in a child. Pediatric Neurology, 2001, 24, 310-312.	2.1	19
134	Leveraging Natural History Data in One- and Two-Arm Hierarchical Bayesian Studies of Rare Disease Progression. Statistics in Biosciences, 0, , 1.	1.2	0